title: Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
abstract: The Women's Health Initiative (WHI) randomized trials found that use of combined estrogen and progestin menopausal hormone therapy (CHT) increases breast cancer risk, but use of unopposed estrogen hormone therapy (EHT) does not. However, several questions regarding the impact of hormone use on risk of different types of breast cancer and what thresholds of use confer elevations in risk remain. We conducted a population-based case-control study among women 55-74 years of age to assess the association between menopausal hormone use and risk of invasive ductal and invasive lobular breast carcinomas. Associations were evaluated using polytomous logistic regression and analyses included 880 ductal cases, 1,027 lobular cases, and 856 controls. Current EHT and CHT use were associated with 1.6-fold [95 % confidence interval (CI): 1.1-2.2] and 2.3-fold (95 % CI: 1.7-3.2) increased risks of lobular breast cancer, respectively, but neither was associated with risk of ductal cancer. Lobular cancer risk was increased after 9 years of EHT use, but after only 3 years of CHT use. Evidence across more than a dozen studies indicates that lobular carcinoma is the type of breast cancer most strongly influenced by menopausal hormones. Here, we characterize what thresholds of duration of use of both EHT and CHT that confer elevations in risk. Despite the rapid decline in hormone therapy use the WHI results were published, study of the hazards associated with these medications remains relevant given the estimated 38 million hormone therapy prescriptions that are still filled in the United States annually.
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, cili@fhcrc.org.
authors.forename: Christopher I
authors.initials: CI
authors.lastname: Li
authors.forename: Janet R
authors.initials: JR
authors.lastname: Daling
authors.forename: Kara L
authors.initials: KL
authors.lastname: Haugen
authors.forename: Mei Tzu Chen
authors.initials: MT
authors.lastname: Tang
authors.forename: Peggy L
authors.initials: PL
authors.lastname: Porter
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Malone
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D018275:Carcinoma, Lobular / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D011372:Progestins / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism; D018570:Risk Assessment
chemical_list: D004967:Estrogens; D011372:Progestins; D011960:Receptors, Estrogen
references.citation: Int J Cancer. 2008 Aug 15;123(4):933-41
references.pmid: 18506692
references.citation: Cancer Causes Control. 2003 Apr;14(3):225-33
references.pmid: 12814201
references.citation: J Natl Cancer Inst Monogr. 2005;(35):106-12
references.pmid: 16287895
references.citation: Cancer. 2002 Dec 15;95(12):2455-64
references.pmid: 12467057
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1260-8
references.pmid: 18323549
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2773-80
references.pmid: 18086787
references.citation: Cancer. 2009 Mar 1;115(5):936-45
references.pmid: 19156895
references.citation: Lancet Oncol. 2006 Nov;7(11):910-8
references.pmid: 17081916
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96
references.pmid: 19336542
references.citation: JAMA. 2003 Jun 25;289(24):3243-53
references.pmid: 12824205
references.citation: Am J Epidemiol. 1992 Dec 1;136(11):1393-9
references.pmid: 1488966
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50
references.pmid: 18199710
references.citation: Int J Cancer. 2006 Mar 1;118(5):1285-91
references.pmid: 16170777
references.citation: JAMA. 2003 Jun 25;289(24):3254-63
references.pmid: 12824206
references.citation: Cancer. 2000 Jun 1;88(11):2570-7
references.pmid: 10861435
references.citation: Br J Cancer. 2006 Jul 3;95(1):123-9
references.pmid: 16755295
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600
references.pmid: 12101105
references.citation: Breast Cancer Res. 2010;12(6):R106
references.pmid: 21143857
references.citation: JAMA. 2002 Feb 13;287(6):734-41
references.pmid: 11851540
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3150-60
references.pmid: 18990757
references.citation: J Clin Oncol. 2002 Feb 1;20(3):699-706
references.pmid: 11821451
references.citation: Breast Cancer Res. 2006;8(1):R11
references.pmid: 16507159